CoChat

Cost assessment of health interventions and diseases

Open access
Fautrel, Bruno, Boonen, Annelies, de Wit, Maarten, Grimm, Sabine, Joore, Manuela, Guillemin, Francis · 2020 · RMD Open

The DOI matches its Crossref record; 21 of the 23 references it cites were found in a registry or an index.

Abstract

Health resource use and identification of related costs are two essential steps in health economics assessment. The elicited costs will be balanced with health outcome improvement and enable the comparison of different diagnostic procedures or therapeutic strategies from a health economic point of view. The cost typology can be disentangled in three main components, that is, direct cost related to health resource use, indirect costs related to productivity loss and sometimes intangible costs (costs related to pain and suffering). These costs can be elicited from different perspectives depending on the general aim of the assessment: payer, societal perspective or patient perspective. Practically, the first step corresponds to the quantification of health resource use, that is, number of consultations, biological or imaging workups, hospitalisation, dispensed medication units or days on sick leave. It can be done by specific self-questionnaires or by access to insurance health databases. The second step is then to value each health resource use item, based on available public databases—either produced by insurance entities or statistics institute—providing the unit costs for each item. Importantly, substantial variability does exist in the costing exercise, requiring accepting a certain uncertainty around cost estimates. This can be taken into account by sensitivity analyses, which capture in what extent measurement error can impact cost assessment, depending on different hypotheses or assumptions. One essential element of health economic assessment is the identification of costs incurred by or associated with a specific health condition for a study on the economic burden of a disease—cost-of-illness study—or with a given diagnostic or therapeutic intervention in the context of health technology assessment in which these costs are compared with the alternative reference strategy—cost-effectiveness study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/rmdopen-2020-001287

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Cost typology.
Figure 1 Cost typology.CC BY · PubMed Central
Figure 2 Concepts behind worker productivity: absenteeism and presenteeism.7
Figure 2 Concepts behind worker productivity: absenteeism and presenteeism.7CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 74

Metadata

Authors
Fautrel, B., Boonen, A., de Wit, M., Grimm, S., Joore, M., & Guillemin, F.
Affiliations
  • Inserm (FR)
  • Maastricht University Medical Centre (NL)
  • Patient Research Partner, EULAR, Zaltbommel, Netherlands
  • EA 4360 APEMAC, School of Public Health, Nancy, France
Corresponding author
Fautrel, Bruno
Venue
RMD Open
Publisher
BMJ
Published
2020-11
Volume
6
Issue
3
Pages
e001287
ISSN
2056-5933 (ISSN-L)
OpenAlex
W3097229587
Cited by
63
References
23
Citations by year
2026: 18 · 2025: 17 · 2024: 14 · 2023: 7 · 2022: 4 · 2021: 1 · 2020: 2
FWCI
2.98
Type
journal article
Language
en
Open access
Locations
  • RMD Open (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • Research Publications (Maastricht University) (submittedVersion, cc-by)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
Funders
  • Amgen
  • Eli Lilly and Company
  • Pfizer
  • Biogen
  • Celgene
  • Celltrion
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Global Health Care Issues
  • Physical Sciences › Engineering › Building and Construction › Life Cycle Costing Analysis
Keywords
cost evaluation, health care utilization, direct costs, indirect costs, productivity loss, intangible costs, cost database, sensitivity analysis, economic burden of disease, economic burden, health technology assessment, cost-effectiveness
MeSH terms
Cost-Benefit Analysis, Hospitalization, Humans, Cost of Illness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost assessment of health interventions and diseases. https://app.cochat.ai/papers/10.1136/rmdopen-2020-001287
The paper
Fautrel, B., Boonen, A., de Wit, M., Grimm, S., Joore, M., & Guillemin, F. (2020). Cost assessment of health interventions and diseases. RMD Open. https://doi.org/10.1136/rmdopen-2020-001287

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.